Ubs Group Ag Supernus Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 108,858 shares of SUPN stock, worth $4.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

108,858

Previous 80,086 35.93%

Holding current value

$4.26 Million

Previous $2.14 Million 58.45%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$25.77 - $35.16 $741,454 - $1.01 Million	28,772 Added 35.93%	108,858 $3.39 Million
Q2 2024 Aug 13, 2024	BUY	$25.99 - $33.85 $403,936 - $526,096	15,542 Added 24.08%	80,086 $2.14 Million
Q1 2024 May 13, 2024	SELL	$27.11 - $35.17 $23,721 - $30,773	-875 Reduced 1.34%	64,544 $2.2 Million
Q4 2023 Feb 09, 2024	BUY	$22.72 - $29.68 $1.05 Million - $1.38 Million	46,390 Added 243.79%	65,419 $1.89 Million
Q3 2023 Nov 09, 2023	SELL	$27.57 - $32.91 $961,751 - $1.15 Million	-34,884 Reduced 64.7%	19,029 $524,000
Q2 2023 Aug 11, 2023	BUY	$29.91 - $38.73 $427,054 - $552,986	14,278 Added 36.02%	53,913 $1.62 Million
Q1 2023 May 12, 2023	BUY	$34.93 - $42.03 $404,244 - $486,413	11,573 Added 41.24%	39,635 $1.44 Million
Q4 2022 Feb 08, 2023	BUY	$31.09 - $37.88 $637,873 - $777,183	20,517 Added 271.93%	28,062 $1 Million
Q3 2022 Nov 10, 2022	BUY	$28.79 - $35.41 $171,617 - $211,079	5,961 Added 376.33%	7,545 $256,000
Q2 2022 Aug 10, 2022	SELL	$25.33 - $34.25 $2.08 Million - $2.81 Million	-82,180 Reduced 98.11%	1,584 $45,000
Q1 2022 May 16, 2022	SELL	$28.51 - $32.9 $434,349 - $501,231	-15,235 Reduced 15.39%	83,764 $2.71 Million
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $2.53 Million - $3.28 Million	95,951 Added 3148.0%	98,999 $2.89 Million
Q3 2021 Nov 15, 2021	SELL	$23.54 - $31.39 $496,576 - $662,172	-21,095 Reduced 87.38%	3,048 $81,000
Q2 2021 Aug 13, 2021	SELL	$26.72 - $33.19 $4.03 Million - $5.01 Million	-151,006 Reduced 86.22%	24,143 $744,000
Q1 2021 May 12, 2021	SELL	$24.15 - $31.45 $150,526 - $196,027	-6,233 Reduced 3.44%	175,149 $4.59 Million
Q4 2020 Feb 11, 2021	BUY	$17.7 - $25.81 $2.91 Million - $4.25 Million	164,612 Added 981.59%	181,382 $4.56 Million
Q3 2020 Nov 12, 2020	SELL	$20.2 - $25.05 $261,529 - $324,322	-12,947 Reduced 43.57%	16,770 $350,000
Q2 2020 Jul 31, 2020	SELL	$17.09 - $24.89 $189,886 - $276,552	-11,111 Reduced 27.21%	29,717 $706,000
Q1 2020 May 01, 2020	SELL	$14.45 - $24.69 $184,194 - $314,723	-12,747 Reduced 23.79%	40,828 $734,000
Q4 2019 Feb 14, 2020	SELL	$19.93 - $29.13 $2.18 Million - $3.19 Million	-109,625 Reduced 67.17%	53,575 $1.27 Million
Q3 2019 Nov 14, 2019	SELL	$25.47 - $33.37 $13.6 Million - $17.8 Million	-533,062 Reduced 76.56%	163,200 $4.49 Million
Q2 2019 Aug 14, 2019	BUY	$29.96 - $38.87 $596,533 - $773,940	19,911 Added 2.94%	696,262 $23 Million
Q1 2019 May 14, 2019	BUY	$32.77 - $41.99 $10.7 Million - $13.7 Million	325,468 Added 92.76%	676,351 $23.7 Million
Q4 2018 Feb 14, 2019	BUY	$30.84 - $49.51 $867,930 - $1.39 Million	28,143 Added 8.72%	350,883 $11.7 Million
Q3 2018 Nov 14, 2018	BUY	$42.7 - $56.55 $12.5 Million - $16.6 Million	293,120 Added 989.6%	322,740 $16.3 Million
Q2 2018 Aug 14, 2018	BUY	$44.1 - $59.85 $673,583 - $914,148	15,274 Added 106.47%	29,620 $1.77 Million
Q1 2018 May 15, 2018	BUY	$37.15 - $46.9 $23,813 - $30,062	641 Added 4.68%	14,346 $657,000
Q4 2017 Feb 14, 2018	SELL	$36.4 - $42.6 $1.12 Million - $1.31 Million	-30,817 Reduced 69.22%	13,705 $546,000
Q3 2017 Nov 14, 2017	BUY	$36.75 - $49.65 $1.09 Million - $1.48 Million	29,740 Added 201.19%	44,522 $1.78 Million
Q2 2017 Aug 14, 2017	SELL	N/A	-158 Reduced 1.06%	14,782 $637,000
Q1 2017 Nov 14, 2017	BUY	N/A	14,940	14,940 $468,000

Others Institutions Holding SUPN

# of Institutions

284

Shares Held

60.5M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.09B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account